Stopping androgen treatment in patients with HAE - characterization of reasons and protocols and development of advice for patients and physicians

Recruiting

• Conditions: D84.1; Defects in the complement system

• Registration Number: DRKS00024439
• Lead Sponsor: Klinik für Dermatologie, Allergologie und Venerologie, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Patients with hereditary angioedema (HAE),
in whom therapy with androgens has been discontinued.

Exclusion Criteria

Patients with hereditary angioedema who have not taken androgens.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine the reasons and circumstances that led patients with hereditary angioedema (HAE) to discontinue prophylactic treatment with androgens.

Secondary Outcome Measures

Name	Time	Method
1) Characterise the reasons why patients with HAE discontinue the use of androgens for long-term prophylaxis.<br>2) Identify what protocols are in place for HAE patients to discontinue the use of androgens.<br>3) Generate data that informs how androgen use can be discontinued for patients and clinicians.<br>